Skip to content
HW190903 CAR-TCR Europe Homepage Banner compressed

A Glimpse of What to Expect

Dedicated to the Delivery of Safe, Effective and Commercially Viable CAR and TCR Immunotherapies for Liquid and Solid Tumours

What is the CAR-TCR Summit Europe?

Returning for the third year due to popular demand, the CAR-TCR Summit Europe is the definitive platform for the European community to tackle the technical bottlenecks limiting the translation, scale and delivery of CAR and TCR therapies to patients in need.

Providing you with the most comprehensive program to grace this side of the pond, across 4 days this summit will drill deeper into the innovations used to break the glass ceiling in manufacturing, safety management and patient accessibility.

Who is the CAR-TCR Summit for?

This meeting is exclusively curated for CAR and TCR drug developers actively working to engineer a cancer free world.

Bringing together the top minds from large pharma, biotech, academia and regulatory boards, join your community to network, share ideas and hear lessons learned to advance your own pipeline towards clinical and commercial success. 

Overcome regulatory challenges to harmonize the EMA regulatory process with clinical experience from Medigene and Celgene, whilst learning from gamechangers from across the globe like Gracell and Immatics Biotherapeutics to disrupt current manufacturing norms to improve patient access.

Why is it paramount that your team attends?

Join forces with the CAR-TCR community to drive innovation. Through collaboration and frank, open conversations, as a field you can you can advance construct design to drive efficacy in solid tumours whilst characterizing the optimal product to improve persistence and durability.

Whether you are managing clinical trials or responsible for devising pricing models, this meeting can support your whole team to develop the tools needed to deliver on the promise of personalized CAR and TCR therapies.

Click here to download the full event guide. Next earlybird ends the 18th of November.

CAR_TCR-Scientific-Advisory-board

Why is it paramount that your team attends?

Join forces with the CAR-TCR community to drive innovation. Through collaboration and frank, open conversations, as a field you can you can advance construct design to drive efficacy in solid tumours whilst characterizing the optimal product to improve persistence and durability.

Whether you are managing clinical trials or responsible for devising pricing models, this meeting can support your whole team to develop the tools needed to deliver on the promise of personalized CAR and TCR therapies.

Click here to download the full event guide. Next earlybird ends the 13th of December.

"An impactful event that is a must-do for anyone working on CAR-TCR therapies."

Bio Rad Logo
Abbott testimonial on success of CAR-TCR summit europe

The CAR-TCR Experience

Workshop Day

9 opportunities to join engaging, discussion-based and data driven workshops spanning translation through to commercialization.

Each providing you with a 2 hour opportunity to ask your questions with a key opinion leader and a room full of expertise to gain actionable insights on the key challenges including:

  • Driving success in solid tumour indications
  • Innovating analytical development to reduce time and cost
  • Build a clinical trial structure to meet unique trial needs

2 Summit Days:
3 Tracks

Drilling deep into the most important bottlenecks in the field, this 3 tracked agenda will provide your whole team with a comprehensive overview of the technical challenges limiting the full pharmaceutical landscape with dedicated content focusing on:

  • Translation
  • Manufacturing
  • Development & Commercialization

Bring your team to divide and conquer ensuring your whole company can benefit from the full range of world-class expertise being showcased.

Focus Day

Take advantage of this invaluable opportunity to further your learning with dedicated content showcasing:

  • Solid Tumour Innovations
  • Clinical Management

With limited efficacy shown in solid tumours, and challenges in the operational running of CAR and TCR therapies in Europe, this is an unmissable opportunity to network with like-minded individuals who’s work is focused to advance these areas.

World-Class Speaker Faculty

Helen-Tayton Martin

Helen Tayton-Martin
Chief Business Officer
Adaptimmune

Annie Hubert

Annie Hubert
Senior Director, Section & Public Policy
Alliance for Regenerative Medicine

Michael Koslowski

Michael Koslowski
CMO
GammaDelta Therapeutics

William Cao

William Wei Cao
CEO
Gracell Biotechnologies Group

Lothar Germeroth

Lothar Germeroth
SVP, MD
Juno Therapeutics

John Johnston

John Johnston
Clinical Assessor
MHRA

Deborah Morrison

Deborah Morrison
Principal Scientific Advisor
National Institute for Health & Clinical Excellence

Reuben Benjamin

Reuben Benjamin
Consultant Haematologist
Kings College Hospital NHS

Proud to Partner With

Lead Partner

Expertise Partners

Program Partners

Hosting Partners

Exhibitors

Other Events in the CAR-TCR Series